Hematological findings in coronavirus disease 2019: indications of progression of disease
Abstract Coronavirus disease 2019 (COVID-19) is a new human infectious disease. The etiology for this outbreak is a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Thus far, related research on COVID-19 is still in preliminary stage. This paper summarized the latest outcomes of corresponding study from Chinese centers and clarified the hematopoietic abnormality caused by SARS-CoV-2 and potential mechanism. Lymphopenia was common in the early stage after the onset of COVID-19. A significant decrease was observed in peripheral CD4+ and CD8+ T lymphocytes. As the illness progressed, neutrophilia emerged in several cases, and patients with severe critical pulmonary conditions showed higher neutrophils than common type. Thrombocytopenia was resulting from the consumption and/or the reduced production of platelets in damaged lungs. Anemia was not observed notably, but the decrease in hemoglobin was frequent. The activation of monocyte-macrophage system aggravates the immune damage of lung and other tissues, which leads to the increase of D-dimer, prothrombin time, and platelet consumption..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
---|---|
Enthalten in: |
Annals of hematology - 99(2020), 7 vom: 03. Juni, Seite 1421-1428 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Liu, Xiaoqing [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
COVID-19 |
doi: |
10.1007/s00277-020-04103-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR040141470 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR040141470 | ||
003 | DE-627 | ||
005 | 20230519104416.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00277-020-04103-5 |2 doi | |
035 | |a (DE-627)SPR040141470 | ||
035 | |a (SPR)s00277-020-04103-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.86 |2 bkl | ||
100 | 1 | |a Liu, Xiaoqing |e verfasserin |4 aut | |
245 | 1 | 0 | |a Hematological findings in coronavirus disease 2019: indications of progression of disease |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Coronavirus disease 2019 (COVID-19) is a new human infectious disease. The etiology for this outbreak is a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Thus far, related research on COVID-19 is still in preliminary stage. This paper summarized the latest outcomes of corresponding study from Chinese centers and clarified the hematopoietic abnormality caused by SARS-CoV-2 and potential mechanism. Lymphopenia was common in the early stage after the onset of COVID-19. A significant decrease was observed in peripheral CD4+ and CD8+ T lymphocytes. As the illness progressed, neutrophilia emerged in several cases, and patients with severe critical pulmonary conditions showed higher neutrophils than common type. Thrombocytopenia was resulting from the consumption and/or the reduced production of platelets in damaged lungs. Anemia was not observed notably, but the decrease in hemoglobin was frequent. The activation of monocyte-macrophage system aggravates the immune damage of lung and other tissues, which leads to the increase of D-dimer, prothrombin time, and platelet consumption. | ||
650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Lymphopenia |7 (dpeaa)DE-He213 | |
650 | 4 | |a Neutrophilia |7 (dpeaa)DE-He213 | |
650 | 4 | |a Thrombocytopenia |7 (dpeaa)DE-He213 | |
650 | 4 | |a Hemoglobin |7 (dpeaa)DE-He213 | |
700 | 1 | |a Zhang, Run |e verfasserin |4 aut | |
700 | 1 | |a He, Guangsheng |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Berlin : Springer, 1955 |g 99(2020), 7 vom: 03. Juni, Seite 1421-1428 |w (DE-627)SPR003573435 |w (DE-600)1458429-3 |x 1432-0584 |7 nnns |
773 | 1 | 8 | |g volume:99 |g year:2020 |g number:7 |g day:03 |g month:06 |g pages:1421-1428 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00277-020-04103-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.86 |q ASE |
951 | |a AR | ||
952 | |d 99 |j 2020 |e 7 |b 03 |c 06 |h 1421-1428 |